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Abstract 
Background: Exercise is a well‑accepted strategy to improve lipid and inflammatory profile in individuals with type 
2 diabetes (T2DM). However, the exercise intensity having the most benefits on lipids and inflammatory markers in 
patients with T2DM remains unclear. We aimed to analyse the impact of a 1‑year combined high‑intensity interval 
training (HIIT) with resistance training (RT), and a moderate continuous training (MCT) with RT on inflammatory and 
lipid profile in individuals with T2DM.
Methods: Individuals with T2DM (n = 80, aged 59 years) performed a 1‑year randomized controlled trial and were 
randomized into three groups (control, n = 27; HIIT with RT, n = 25; MCT with RT, n = 28). Exercise sessions were super‑
vised with a frequency of 3 days per week. Inflammatory and lipid profiles were measured at baseline and at 1‑year 
follow‑up. Changes in inflammatory and lipid markers were assessed using generalized estimating equations.
Results: After adjusting for sex, age and baseline moderate‑to‑vigorous physical activity (MVPA), we observed a 
time‑by‑group interaction for Interleukin‑6 (IL‑6) in both the MCT with RT (β = − 0.70, p = 0.034) and HIIT with RT 
(β = − 0.62, p = 0.049) groups, whereas, only the HIIT with RT group improved total cholesterol (β = − 0.03, p = 0.045) 
and LDL‑C (β = − 0.03, p = 0.034), when compared to control. No effect was observed for C‑reactive protein (CRP), 
cortisol, tumour necrosis factor‑α (TNF‑α), soluble form of the haptoglobin‑hemoglobin receptor CD163 (sCD163), 
triglycerides and HDL‑C in both groups (p > 0.05).
Conclusions: Favorable adaptations on IL‑6 were observed in both the HIIT and MCT combined with RT groups fol‑
lowing a long‑term 1‑year exercise intervention in individuals with T2DM. However, only the HIIT with RT prevented 
further derangement of total cholesterol and LDL‑C, when compared to the control group. Therefore, in order to 
encourage exercise participation and improve inflammatory profile, either exercise protocols may be prescribed, 
however, HIIT with RT may have further benefits on the lipid profile.
Trial registration Clinicaltrials.gov ID: NCT03144505
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Background
Individuals with type 2 diabetes (T2DM) have a height-
ened risk of all-cause mortality and cardiovascular dis-
ease (CVD), especially those with traditional CVD risk 
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factors, such as hypertension, hyperglycaemia, abdomi-
nal obesity, and dyslipidaemia [1]. Low-grade sys-
temic inflammation has been suggested as the common 
denominator linking T2DM, insulin resistance, endothe-
lial dysfunction, metabolic syndrome, and CVD [2]. 
When released by adipose tissue as adipokines, tumour 
necrosis factor-α (TNF-α) and interleukin-6 (IL-6) pro-
mote low-grade systemic inflammation, which in turn is 
associated with chronic deleterious conditions such as 
insulin resistance, T2DM and obesity [2–5]. Another bio-
marker, connecting low-grade inflammation and T2DM, 
is the soluble form of the haptoglobin-hemoglobin 
receptor CD163 (sCD163), with observational studies 
suggesting that individuals with obesity have increased 
concentrations of sCD163 [6] putting them at higher risk 
for T2DM [7].
Exercise, especially the combination of both aerobic 
and resistance training (RT) [8], has many health ben-
efits for patients with T2DM, including improved body 
composition [9, 10], insulin sensitivity [10–12], lipid pro-
file, and reduced low-grade systemic inflammation [13]. 
However, exercise permutations, such as in the duration 
and intensity of the exercise performed, may influence 
the inflammatory and lipid profile differently. Recently, 
high-intensity interval training (HIIT) has emerged as a 
viable alternative in several conditions including those 
with CVD [14], obesity [15], and diabetes [16], while 
having the same or even superior health benefits, to 
that of the more commonly performed exercise modal-
ity of moderate continuous training (MCT) [15–17]. In 
fact, a previous review with T2DM individuals suggests 
that short to medium-term HIIT interventions improve 
glycaemic control, lipid profile, body composition, and 
cardiorespiratory fitness [18]. However, the same review 
suggested that there was no consensus on the long-term 
effects of HIIT, nor the effectiveness of HIIT vs. MCT on 
lipid profile in individuals with T2DM, mainly owing to 
the inexistence of longer interventions or the reduced 
number of randomized control trials (RCT) analys-
ing both protocols. As far as the inflammatory profile 
goes, just two non-RCTs analysed the impact of HIIT in 
individuals with T2DM, with both having a short inter-
vention duration (< 12-weeks) and with the results sug-
gesting limited impact [19, 20]. Given that currently the 
information related with HIIT and its impact on both 
the lipid and inflammatory profile is derived from short 
to medium-term investigations (≤ 24-weeks), it is para-
mount to understand if these previous findings can be 
replicated in longer-term controlled exercise interven-
tions, as HIIT has been shown to be a highly demanding 
type of exercise [21].
To the best of our knowledge, no investigation has ana-
lysed the long-term impact of combined aerobic exercise 
of different intensities with RT on both the inflammatory 
and lipid profile in individuals with T2DM. Therefore, 
the present investigation aimed to analyse the effects of 
a 1-year RCT consisting of a control, a combined MCT 
with RT, and a combined HIIT with RT group, on the 
inflammatory and lipid profile in individuals with T2DM.
Methods
Participants, randomization, and blinding
This investigation was part of a larger RCT performed 
between February 2014 to July 2016 at the Exercise and 
Health Laboratory, Faculty of Human Kinetics, Univer-
sity of Lisbon, and was carried out following the recom-
mendations of the Declaration of Helsinki for Human 
Studies. The protocol was approved by the Ethics Com-
mittee of the Portuguese Diabetes Association (approval 
number: 07/17/2013). Written informed consents were 
obtained from all participants.
The complete study protocol has been previously 
published [22]. Briefly, individuals with T2DM were 
recruited to analyse the impact of a 1-year exercise inter-
vention with different intensities on glycated haemoglo-
bin (HbA1c) (clinicaltrials.gov ID:NCT03144505). Eighty 
patients were recruited within the Lisbon Metropoli-
tan Area (Fig.  1) [22], and posteriorly randomized into 
three groups (control, HIIT with RT or MCT with RT). 
An external researcher, with an allocation ratio of 1:1:1, 
used a computer-generated list of random numbers, for 
the randomization process. The researchers performing 
the assessments were blinded to group randomization. 
Inclusion criteria for participants included adults diag-
nosed with T2DM [23], age between 30 and 75 years old, 
no major micro or macro vascular complications from 
diabetes, body mass index < 48  kg/m2, and no limita-
tions that would prevent them from practicing exercise. 
The main outcome power and sample size calculations 
(G-Power, Version 3.1.3) were based on a predicted 
HbA1c difference of 0.66% with a SD of 1.2%, α = 0.05, 
1-β = 0.80 and an expected dropout rate of 10% [24]. For 
this analysis, the power and sample size calculations were 
based on changes in whole-body fat, which is related with 
overall inflammatory profile. Given a predicted whole-
body fat difference of 2.7%, with a SD of 1.7%, α = 0.05, 
1-β = 0.80, the sample used on this study was powered 
for this analysis [16].
The control group had an initial standard physical 
activity (PA) recommendation session and no struc-
tured exercise. All of the exercise groups (i.e. the MCT 
and HIIT group) had three supervised exercise sessions 
per week, monitored with a heart rate polar band (Polar 
T-31, USA). The exercise programs of both groups were 
developed to have matched energy expenditure, with a 
weekly target of 10 kcal/kg, which was updated monthly 
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for their body weight and every 3 months for their peak 
oxygen consumption.
The MCT and HIIT groups had an exercise periodi-
zation for the 1-year divided in two and three phases, 
respectively. Heart rate reserve (HRR), calculated 
through the Karvonen formula [25], was used to achieve 
prescribed intensities. Phase 1 was identical for both 
groups (weeks 1–4), with patients performing continu-
ous cycling of moderate-intensity (40–60% of the HRR) 
with durations increasing from 15 min to 25 by the end 
of week 4. The MCT group had only one additional 
phase (training phase, weeks 5–52), where participants 
Fig. 1 Study flow chart
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exercised at 40 to 60% of the HRR, with durations based 
on prescribed energy expenditure targets.
In the HIIT group, during phase 2 (5–8  weeks), 
patients performed bouts of 2  min of cycling at 70% of 
the HRR followed by 1 min at 40–60% of the HRR (weeks 
5–6), and increased to bouts of 80% (1.5 min) of the HRR 
followed by 1  min at 40–60% of the HRR (weeks 7–8), 
while maintaining energy expenditure targets. In phase 3 
(weeks 9–52), participants in the HIIT group performed 
1 min of exercise at 90% of their HRR followed by 1 min 
resting at 40-60% of the HRR. Both the MCT and HIIT 
group were further complemented with a whole-body 
RT, after the aerobic component, which included 1 set of 
10–12 RM of eight exercises (seated row, pulldown, chest 
press, shoulder press, leg press, one leg lung, dead bug 
and regular plank).
Anthropometry and body composition
Patients were weighed on an electronic scale, to the near-
est 0.01  kg while wearing minimal clothes (Seca, Ham-
burg, Germany). Height was measured to the nearest 
0.1  cm with a stadiometer (Seca, Hamburg, Germany). 
Waist circumference was taken according to the stand-
ardized procedures of the National Institute of Health 
[26].
Dual energy X-ray absorptiometry (Hologic Explorer-
W, Waltham, USA) was used to assess regional and total 
body fat, following standardized protocols and proce-
dures set out by the manufacturer. Whole-body fat index 
(WBFI) and abdominal fat index (AFI) were calculated by 
dividing the total and abdominal fat mass by the square 
of the height (kg/m2).
Objective measures of moderate‑to‑vigorous physical 
activity
Moderate-to-vigorous PA (MVPA) was assessed by accel-
erometry (ActiGraph, GT3X + , FL, USA) at baseline 
prior to the start of the intervention. All participants 
used the accelerometer for 7 days, on the right hip. The 
devices were activated on raw mode with a 100 Hz fre-
quency and later transformed into 15-s epochs. The Troi-
ano et al. [27] cut points and wear time validation criteria 
were used.
Laboratory measurements
Blood collection was performed in a seated position from 
the antecubital vein at rest after an overnight fast into 
dry tubes and into tubes containing ethylenediamine-
tetraacetic acid as an anticoagulant. Biological samples 
were centrifuged at 500g at 4  °C for 15-min and plasma 
samples were frozen at − 80 °C for posterior analysis.
Serum samples were used to analyse the lipid profile 
of the participants, including the quantification of total 
cholesterol, LDL-C and HDL-C cholesterol, and triglyc-
erides using colored enzymatic tests in an automated 
analyser (auto analyser Olympus AU640, Beckman Coul-
ter). Plasma samples were then used for TNF- α, IL-6, 
sCD163, C-reactive protein (CRP), and cortisol quantifi-
cation using commercial ELISA kits (DiaSource Immuno 
Assays S.A for TNF-α, IL6, and Cortisol; IBL Interna-
tional GMBH for CRP; and DC1630, R&D Systems for 
sCD163).
Changes in the lipid and inflammatory profile were 
analyzed at baseline and at the 1-year follow-up.
Statistical analysis
Data analyses were performed using SPSS Statistics ver-
sion 22.0 (SPSS Inc., an IBM Company, Chicago, Illi-
nois, USA). Results are presented as mean ± SD for 
all normally distributed outcomes and as median and 
inter-quartile range for skewed outcomes. Comparisons 
between groups were performed using the Chi-squared 
test for sex proportions between groups, and the para-
metric independent sample ANOVA test with a Bonfer-
roni post hoc analysis for normally distributed variables 
or the non-parametric Kruskal–Wallis test in absence of 
normality.
Between-group and within-group effects for the lipid 
inflammatory profile were performed using generalized 
estimating equations followed by a least significant dif-
ference post hoc test. Models were adjusted for potential 
confounders (i.e. age, sex and baseline MVPA). All the 
outcomes went through an intention-to-treat analysis 
(ITTA). An additional per-protocol analysis (PPA) was 
performed in only those who completed both assess-
ments (i.e. baseline and 1-year), had at least 70% attend-
ance to all the exercise sessions, and in those without 
substantial changes in pharmacological therapy [22]. No 
changes were made to dyslipidemia and hypertension 
medication, however, individuals with major changes in 
anti-hyperglycemic medication, such as transitioning to 
insulin, were removed from the (PPA).
Results
Table 1 shows the baseline characteristics of the individu-
als by intervention group and in the ITTA and PPA. No 
significant differences between groups were observed 
at baseline in both analyses, except for baseline time 
spent in MVPA (Table  1). For the control, MCT and 
HIIT groups, the dropout rates were 11%, 18%, and 24%, 
respectively (Fig. 1). In the PPA, individuals in the MCT 
and HIIT group trained for 45.0 ± 7.1  min/session and 
33.1 ± 6.4  min/session, and had mean percent training 
adherences of 86.2% and 86.8%, respectively. Three indi-
viduals reported injuries during the intervention, two in 
the HIIT group while performing the leg-press exercise 
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and one from the MCT group while performing the back-
row exercise. The cardiovascular event reported in the 
flow chart took place during the participant’s day-to-day 
routine and was not related to the intervention.
Table 2 presents the body composition, the inflamma-
tory (IL-6, TNF-α, CRP, sCD163 and cortisol) and lipid 
(LDL-C, HDL-C, and triglycerides) profile outcomes 
assessed at baseline and at follow-up by group, as well 
as the respective time-by-group interactions between 
each intervention group (MCT vs. HIIT vs. control) 
using the ITTA. All models were adjusted for sex, age, 
and baseline MVPA. Following adjustments, the ITTA 
analysis suggested that the HIIT prevented further 
derangement on total cholesterol (β = − 0.03, p = 0.045) 
and LDL-C (β = − 0.03, p = 0.034) when compared 
to the control, whereas the MCT had no effect on the 
lipid profile variables (p > 0.05). Only the MCT group 
had changes in WBFI (β = − 0.06, p = 0.025) and AFI 
(β = − 0.01, p = 0.011). Regarding the inflammatory 
profile, both the MCT (β = − 0.70, p = 0.034) and HIIT 
(β = − 0.62, p = 0.049) prevented further derangement 
(p < 0.05) in the levels of IL-6 following the 1-year inter-
vention, when compared to controls. For the remain-
ing inflammatory variables, no changes (> 0.05) were 
observed for both intervention groups compared to 
controls including the sCD163 biomarker. Moreover, 
there was no time-by-group interaction (p > 0.05) in 
any of the biomarkers measured when comparing both 
exercise groups (i.e. HIIT vs MCT).
Table 3 summarizes the results of the PPA for the lipid, 
inflammatory and body composition profile. As a result 
of the 1-year HIIT and MCT intervention, the HIIT 
group prevented further deterioration of the LDL-C pro-
file (β = − 0.03, p = 0.049), when compared to control. 
On the other hand, no changes were observed between 
both groups and control for the remaining lipid pro-
file variables, including total cholesterol, HDL-C, and 
triglycerides (p > 0.05). Within the inflammatory pro-
file, IL-6 followed the same trend as in the ITTA for the 
MCT group (β = − 0.89, p = 0.047), while there were no 
changes for the HIIT group (β = − 0.72, p = 0.081). For 
both intervention groups, there was no time-by-group 
interaction (p > 0.05) for cortisol, TNF-α, sCD163, and 
CRP, when compared to control. Lastly, in line with the 
results from the ITTA, no time-by-group interaction 
(p > 0.05) was found between MCT and HIIT for any of 
the biomarkers assessed.
Figure  2 depicts data from the absolute values on 
baseline and 1-year follow-up for the C-LDL, total cho-
lesterol, IL-6, sCD163, WBFI and AFI using the ITTA.
Table 1 Baseline characteristics of the participants by group and all sample
AFI android fat index, BMI body mass index, HbA1c glycated hemoglobin, HIIT high-intensity interval training, MCT moderate continuous training, MVPA moderate-to-
vigorous physical activity, WC waist circumference, WBFI whole-body fat index
* Differences between group baseline values (p < 0.05)
†Skewed values are presented as median ± inter quartile range
Intention to treat baseline values Per‑protocol baseline values
Control (n = 27) MCT (n = 28) HIIT (n = 25) p‑value Control (n = 22) MCT (n = 16) HIIT (n = 13) p‑value
Age (years) 59.0 ± 8.1 59.7 ± 6.5 56.7 ± 8.3 0.575 60.8 ± 7.5 60.4 ± 6.8 58.9 ± 7.5 0.814
Woman, no (%) 48.1 53.6 40.0 0.612 50.0 56.3 30.8 0.367
Diabetes Diagnosis (years)† 5.0 ± 3.0 8.0 ± 9.0 5.0 ± 6.0 0.086 4.5 ± 3.25 8.0 ± 9.0 6.0 ± 6.0 0.091
Hypertension medication (%) 48.1 50.0 52.0 0.579 54.5 37.5 53.8 0.538
Oral antidiabetic medication 
(%)
96.3 92.9 84.0 0.388 95.5 93.8 92.3 0.512
Lipid lower medication (%) 33.3 25.0 24.0 0.596 31.8 31.3 23.1 0.341
Weight (kg) 84.1 ± 15.8 82.7 ± 13.3 81.6 ± 16.8 0.906 85.9 ± 15.7 82.0 ± 13.8 84.2 ± 19.2 0.799
Height (cm) 165.5 ± 9.4 163.2 ± 8.4 164.8 ± 8.1 0.545 164.2 ± 9.5 162.9 ± 9.2 166.6 ± 8.1 0.615
BMI (kg/m2) 30.7 ± 5.0 31.1 ± 5.0 30.1 ± 5.7 0.722 31.7 ± 4.7 31.0 ± 5.5 30.2 ± 5.9 0.506
WC (cm) 103.0 ± 12.4 103.8 ± 11.3 102.7 ± 14.3 0.914 105.4 ± 11.2 103.5 ± 12.2 103.3 ± 15.8 0.946
WB Fat Index (kg/m2) 10.5 ± 3.3 11.0 ± 3.4 10.0 ± 3.9 0.725 11.2 ± 2.9 11.0 ± 3.4 10.1 ± 3.9 0.662
AFI (kg/m2) 1.0 ± 0.4 1.1 ± 0.4 1.0 ± 0.4 0.680 1.1 ± 0.3 1.1 ± 0.4 1.0 ± 0.4 0.843
MVPA (min/day)† 18.4 ± 26.4 30.5 ± 4.8 38.9 ± 29.4 0.008* 15.9 ± 23.1 38.1 ± 41.6 38.9 ± 30.1 0.012*
HbA1c (mmol/mol)† 49.7 ± 20.7 53.2 ± 22.7 49.0 ± 12.3 0.545 48.1 ± 16.7 47.2 ± 22.1 50.8 ± 12.6 0.828
HbA1c (%)† 7.4 ± 1.8 7.4 ± 1.9 7.0 ± 1.1 0.545 6.9 ± 1.1 6.9 ± 1.6 6.9 ± 0.9 0.828
VO2peak (ml/kg/min) 25.9 ± 5.5 24.1 ± 3.2 27.1 ± 6.3 0.143 25.1 ± 5.6 23.9 ± 3.7 26.6 ± 5.3 0.345
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Discussion
To the best of our knowledge, this is the first RCT ana-
lysing the long-term impact of combined training with 
different intensities, on lipid and inflammatory profile in 
individuals with T2DM. The main finding was that long-
term HIIT aerobic exercise, while combined with RT, can 
be used to prevent further derangement of total choles-
terol, LDL-C and IL-6 in individuals with T2DM. Regard-
ing the MCT group, we observed favourable changes only 
on IL-6, with no impact on the lipid profile after 1-year 
of intervention. Finally, there was no statistically signifi-
cant difference in any of the biomarkers measured when 
comparing HIIT with RT group with the MCT with RT 
group.
Low-grade systemic inflammation has been indepen-
dently implicated in metabolic disorders, such as insu-
lin resistance and T2DM, and is typically presented with 
elevated levels of pro-inflammatory cytokines (i.e. IL-6, 
TNF-α, and CRP) [28, 29]. On the other hand, exercise 
can be used to prevent or counter the detrimental met-
abolic effects of elevated pro-inflammatory cytokines 
on different organs and tissues of the body [13]. In our 
investigation, both the MCT and HIIT combined with 
RT regimens showed favourable changes in the circulat-
ing levels of IL-6 following 1-year of exercise when com-
pared with the control group, although no results were 
observed for the remaining inflammatory markers. The 
number of investigations that have analysed the impact 
of HIIT on the inflammatory profile in T2DM are scarce, 
with only two short-term interventions (< 12-week dura-
tion) reporting no substantial effects on IL-6, TNF-α, and 
CRP [19, 20].
Similar results to the ones in our investigation were 
found with reduced levels of IL-6, as well as CRP, while 
using a different protocol of high-intensity continuous 
training, either alone or combined with RT, in individu-
als with T2DM [30]. However, only the combination of 
aerobic and RT had a significant impact on the circulat-
ing levels of TNF-α.
Most of the benefits of exercise on the inflamma-
tory profile seem to be mediated by body composi-
tion changes. For instance, without weight loss, a 
twice-weekly progressive aerobic program in patients 
with T2DM did not observe any changes in TNF-α and 
CRP levels following a 6-month intervention [31], which 
follows our findings. On the other hand, a 1-year aerobic 
exercise intervention plus weight loss [32] showed a sig-
nificant reduction in both TNFα and CRP. Moreover, in 
overweight/obese individuals without T2DM, short and 
medium-term interventions have also observed a reduc-
tion in IL-6 following 2 weeks [33], and 16 weeks of HIIT 
[34], where modest weight loss was observed.
Fig. 2 Intention‑to‑treat analysis derived from the GEE mixed model of the 1‑year exercise intervention on total cholesterol, LDL colestherol, IL‑6, 
sCD163, whole body fat and abdominal fat index. Absolute mean values and standard errors of means are presented, with models adjusted for 
sex and baseline MVPA. Abbreviations: HIIT, high‑intensity interval training; LDL‑C, low‑density lipoprotein cholesterol; MCT, moderate continuous 
training. * HIIT vs. control group changes significant at p < 0.05; † MCT vs. control group changes significant at p < 0.05
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Beyond weight loss and the reduction in visceral fat 
mass, there are other proposed mechanisms for the 
improvements in the inflammatory profile following an 
exercise intervention [13, 29]. In fact, it is possible that 
the larger effect size for improvements in IL-6 observed 
in the MCT group combined with RT compared to the 
HIIT group combined with RT could be due to decreases 
in AFI and WBFI, which was not observed in the HIIT 
group. Nevertheless, the HIIT group still had a time-
by-group interaction in IL-6 compared to the controls, 
regardless of body fat loss. Thus, it is possible that other 
mechanisms are responsible for the favourable changes 
in IL-6, such as the increased production of muscular 
anti-inflammatory myokines and the reduction of human 
monocyte Toll-like receptors 2 with exercise [35–37].
Another important finding from this investigation con-
cerns the long-term impact of different exercise permuta-
tions on the sCD163 biomarker. Our results suggest that 
regardless of the exercise group there were no changes 
on the sCD163. The sCD163 molecule is increased after 
macrophage activation, with individuals with higher 
levels of adipose tissue having higher expression of this 
biomarker [38]. In fact, sCD163 has been positively asso-
ciated with, obesity [6] and T2DM [7]. However, little is 
known about the effects of exercise on sCD163, with no 
study addressing the impact of different exercise intensi-
ties on this marker in individuals with T2DM. In individ-
uals with non-alcoholic liver disease, a 3-month lifestyle 
intervention program, with both PA and dietary coun-
selling, reduced the levels of sCD163 [39]. In contrast, 
decreased values have only been observed with dietary-
induced weight loss [6], suggesting that sCD163 changes 
are dependent on body weight loss, particularly that of 
adipose tissue, which leads to a reduction of infiltrated 
active macrophages. Nevertheless, even with total and 
abdominal body fat reduction, as previously reported in 
the main findings of this study [22], the MCT group did 
not display corresponding decreases in sCD163 following 
the 1-year intervention. Future studies are warranted to 
further understand relationships among exercise train-
ing, sCD163, and adiposity in individuals with T2DM.
Regular exercise has also been shown to improve the 
lipid profile in individuals with T2DM [40, 41]. In our 
investigation, only the HIIT group observed significant 
changes in the circulating levels of LDL-C and total cho-
lesterol compared to controls, whereas no changes were 
observed for the MCT group after 1-year of interven-
tion. A recent meta-analysis in individuals with T2DM, 
examined the effects of HIIT and MCT on several bio-
markers, including the lipid profile [42]. The analysis 
suggested that there were no differences between higher 
and moderate exercise intensities. However, the results 
were inconsistent between studies, with two reporting 
no effects of HIIT and MCT on LDL-C, HDL-C, total 
cholesterol and triglycerides [43, 44], and only one study 
observing changes in HDL-C and LDL-C with both HIIT 
and MCT, and decreased total cholesterol with [16]. The 
differences between these results and those reported in 
the present investigation may be explained by the base-
line values of the participants, with most of our partici-
pants having relatively normal ranges of total cholesterol, 
HDL-C, and LDL-C levels, which did not change greatly 
after exercise. However, the biggest impact of the HIIT 
group on the lipid profile lies in differences against the 
control group, who incurred in adverse changes in their 
lipid profile over the course of 1-year without any exer-
cise intervention. Moreover, the exercise protocols dif-
fered substantially between studies [16, 43, 44], with 
none of the interventions using the 1:1 (active-to-rest 
period ratio) protocol on a cycle ergometer and none 
of the interventions having a duration longer than 
16-weeks. Another possible confounding factor is the 
baseline MVPA values (which were higher in the HIIT 
group), since it has been shown that higher physical 
activity intensities may be related with a more favour-
able lipid profile [45]. However, both HIIT and MCT had 
similar frequencies of patients fulfilling the PA guidelines 
and similar levels of cardiorespiratory fitness at baseline. 
Moreover, the results of the intervention remained the 
same after adjusting the models for baseline MVPA.
Given the results of our previous findings on vascular 
function [46], where the HIIT combined with RT had 
superior improvements when compared to MCT, we 
can speculate that the favourable changes in the lipid 
and inflammatory profile observed in the HIIT com-
bined with RT group may have been mediated by some of 
these changes, alongside with other mechanism already 
addressed in the previous manuscript [46]. Nonetheless, 
even though we have shown that HIIT can be a feasible 
option for long-term clinical interventions (1-year), it 
maybe not be a viable solution in a more ecological set-
ting given the physiological and psychological burden 
associated with long-term HIIT [21]. Thus, on the long 
run HIIT may be better suited in combination with 
intermittent periods of lower intensity trainings such as 
MCT to increase participant’s exercise adherence and 
enjoyment.
Despite the encouraging results observed, there are 
limitations in the present investigation that should be 
addressed. First, given that the sample size calculation for 
the D2FIT study was based off of the primary study out-
come (i.e. HbA1c difference) and that for many inflam-
matory markers, such as that of CRP, as well as many of 
the lipid indices are known to exhibit high within-indi-
vidual variability [47], it is likely that the lack of exer-
cise intervention effect observed on many of the lipid 
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and inflammatory parameters was due to small sample 
size. Another limitation involves t he lack of mid-term 
assessments during the 1-year intervention period, 
which did not allow for the assessment of the evolution 
of the inflammatory and lipid profile, especially in the 
first months of the intervention, where the adherence 
to the exercise programs may be higher. In addition, 
energy intake was not controlled during the interven-
tion, which might have affected the lipid profile. As far 
as the strengths of our investigation are concerned, we 
used a 1-year intervention with supervised exercise ses-
sions, which provides, for the first time, information on 
the long-term implications of combined HIIT and MCT 
protocols combined with RT in patients with T2DM.
Conclusions
In conclusion, 1-year of combined training with MCT 
and HIIT induced favourable changes in circulating lev-
els of IL-6, which may reflect the prevention of further 
derangement in the low-grade systemic inflammation 
typical in individuals with T2DM. Nonetheless, only 
HIIT was effective in attenuating the increases observed 
in the control group for both total cholesterol and LDL-
C. Therefore, HIIT may be considered an effective strat-
egy and an alternative to the traditional MCT guidelines, 
with similar or even greater long-term benefits, for 
improving inflammatory and lipid profiles in individuals 
with T2DM.
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